Indian Journal of Rheumatology

LETTER TO EDITOR
Year
: 2020  |  Volume : 15  |  Issue : 6  |  Page : 226-

We are in charge of treating myositis!


Ilke Coskun Benlidayi 
 Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Cukurova University, Adana, Turkey

Correspondence Address:
Dr. Ilke Coskun Benlidayi
Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Cukurova University, Adana
Turkey




How to cite this article:
Benlidayi IC. We are in charge of treating myositis!.Indian J Rheumatol 2020;15:226-226


How to cite this URL:
Benlidayi IC. We are in charge of treating myositis!. Indian J Rheumatol [serial online] 2020 [cited 2021 Apr 15 ];15:226-226
Available from: https://www.indianjrheumatol.com/text.asp?2020/15/6/226/286218


Full Text



Inflammatory myopathy/myositis is an umbrella term that encompasses polymyositis, dermatomyositis, sporadic inclusion-body myositis, immune-mediated necrotizing myopathy, and overlap myositis.[1] The prominent clinical feature is subacute to chronic onset of proximal muscle weakness. Patients may also present with extramuscular symptoms indicating the systemic inflammatory feature of the disease.[2],[3] Multiorgan involvement may include the skin, gastrointestinal system, joints, lungs, and heart.[3] Muscle enzymes, myositis-specific antibodies, electroneuromyography, skeletal muscle imaging, and muscle biopsy are used for diagnosis.[2]

Management of idiopathic inflammatory myositis should involve both pharmacological and nonpharmacological strategies. Pharmacological options vary including corticosteroids, methotrexate, azathioprine, mycophenolate mofetil, intravenous immunoglobulin, cyclophosphamide, cyclosporine, tacrolimus, rituximab, and some other biological disease-modifying anti-rheumatic drugs. On the other hand, nonpharmacological options such as physical, occupational, and speech therapy should be directed meticulously according to patients' needs.[2]

In this regard, a multidisciplinary approach is desired for the management of inflammatory myositis. Hence, we are all in charge of treating myositis [Figure 1]. Let's “collect the inflammatory cells,” “patch the vacuoles,” and “remove the aggregates”!{Figure 1}

References

1Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, Milisenda JC, Grau-Junyent JM, Mammen AL. Classification and management of adult inflammatory myopathies. Lancet Neurol 2018;17:816-28.
2Malik A, Hayat G, Kalia JS, Guzman MA. Idiopathic inflammatory myopathies: Clinical approach and management. Front Neurol 2016;7:64.
3Lundberg IE, de Visser M, Werth VP. Classification of myositis. Nat Rev Rheumatol 2018;14:269-78.